Premium
Control of thrombotic thrombocytopenic purpura by sirolimus in a child with juvenile myelomonocytic leukemia and somatic N‐RAS mutation
Author(s) -
Maschan Michael,
Bobrynina Vlasta,
Khachatryan Lili,
Kalinina Irina,
Solopova Galina,
Avdonin Pavel,
Nasedkina Tatiana,
Novichkova Galina,
Maschan Alexei
Publication year - 2014
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25013
Subject(s) - juvenile myelomonocytic leukemia , medicine , cyclophosphamide , sirolimus , germline mutation , immunology , leukemia , cancer research , haematopoiesis , oncology , mutation , chemotherapy , stem cell , biology , genetics , gene
We describe an infant who developed juvenile myelomonocytic leukemia (JMML) at the age of 6 months. Myeloproliferation was effectively controlled by low‐dose cytosine arabinoside and 13‐cis retinoic acid therapy. Two years after therapy for JMML was stopped, at the age of 5 years, the patient developed autoimmune thrombotic thrombocytopenic purpura (TTP). TTP was transiently controlled by plasma exchange, prednisolone, rituximab, and cyclophosphamide, but relapsed within a short time. Long‐term control of TTP was established by sirolimus. Somatic N‐RAS G38A→Gly13Asp substitution was restricted to hematopoietic cells. The somatic N‐RAS mutation may link myeloproliferation and autoimmunity. Pediatr Blood Cancer 2014; 61:1871–1873. © 2014 Wiley Periodicals, Inc.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom